At the time of writing, RAPT Therapeutics Inc [RAPT] stock is trading at $19.86, down -3.12%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RAPT shares have gain 22.44% over the last week, with a monthly amount glided 92.44%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
RAPT Therapeutics Inc [NASDAQ: RAPT] stock has seen the most recent analyst activity on July 30, 2025, when JP Morgan upgraded its rating to a Neutral but kept the price target unchanged to $14 for it. On December 26, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $10 on the stock. Stifel downgraded its rating to a Hold and decreased its price target to $2 on November 13, 2024. Piper Sandler downgraded its rating to a Neutral and reduced its price target to $2 on November 11, 2024. JP Morgan downgraded its rating to Underweight for this stock on November 11, 2024. In a note dated May 14, 2024, Wolfe Research downgraded an Peer Perform rating on this stock.
For the past year, the stock price of RAPT Therapeutics Inc fluctuated between $5.67 and $26.56. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. RAPT Therapeutics Inc [NASDAQ: RAPT] shares were valued at $19.86 at the most recent close of the market. An investor can expect a potential drop of -54.68% based on the average RAPT price forecast.
Analyzing the RAPT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.68 and Total Capital is -0.68. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that RAPT Therapeutics Inc [NASDAQ:RAPT] has a current ratio of 13.25. As well, the Quick Ratio is 13.25, while the Cash Ratio is 3.21.